

William C Jackson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1777543/publications.pdf>

Version: 2024-02-01

75
papers

2,173
citations

279487

23
h-index

253896

43
g-index

75
all docs

75
docs citations

75
times ranked

3543
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	2.0	15
2	Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients. <i>BJU International</i> , 2022, , .	1.3	2
3	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 278-289.	0.4	4
4	Patient Reported Outcomes for Quality of Life (QOL) By Expanded Prostate Cancer Index (EPIC) on Average 15 Years Post Treatment. <i>Clinical and Translational Radiation Oncology</i> , 2022, , .	0.9	3
5	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. <i>Journal of Clinical Oncology</i> , 2022, 40, 3172-3179.	0.8	14
6	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
7	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	0.8	52
8	The Management of Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 3-23.	0.0	0
9	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
10	Survival, fusion, and hardware failure after surgery for spinal metastatic disease. <i>Journal of Neurosurgery: Spine</i> , 2021, 34, 665-672.	0.9	6
11	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2110950.	2.8	4
12	End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2844-2845.	0.8	4
13	The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 127-134.	0.4	10
14	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
15	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
16	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
17	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.3	19
18	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	0.6	19

#	ARTICLE	IF	CITATIONS
19	Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1881.	3.4	66
20	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	0.8	26
21	Evolving Role of Stereotactic Body Radiation Therapy in the Management of Spine Metastases. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 167-189.	0.8	12
22	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
23	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.	1.0	10
24	Surrogate Endpoints in Localized Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 48-52.	1.0	7
25	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
26	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 659-665.	0.6	149
27	Submandibular gland sparing when irradiating neck level IB in the treatment of oral squamous cell carcinoma. <i>Medical Dosimetry</i> , 2019, 44, 144-149.	0.4	7
28	A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 141, 101-107.	0.3	20
29	In Reply to Slovak etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 696-697.	0.4	0
30	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 628-636.	0.4	20
31	Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2019, 86, E164-E172.	0.6	5
32	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. <i>JAMA Network Open</i> , 2019, 2, e187765.	2.8	17
33	Association of Black Race With Prostate Cancerâ€“Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
34	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.4	247
35	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 599-610.	0.8	8
36	Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1635-1643.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	0.9	28
38	Tissue-based genomics. <i>Current Opinion in Urology</i> , 2019, 29, 598-604.	0.9	3
39	Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 382-390.	0.6	3
40	Changes in prostate orientation due to removal of a Foley catheter. <i>Medical Physics</i> , 2018, 45, 1369-1378.	1.6	13
41	Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 155-162.	1.4	4
42	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018, 35, 21.	1.2	3
43	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	0.9	29
44	Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 950-958.	0.4	59
45	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
46	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	1.3	24
47	Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 131-137.	0.4	18
48	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	1.1	27
49	Organ-Sparing in Radiotherapy for Head-and-Neck Cancer: Improving Quality of Life. <i>Seminars in Radiation Oncology</i> , 2018, 28, 46-52.	1.0	38
50	Knowledge-based treatment planning and its potential role in the transition between treatment planning systems. <i>Medical Dosimetry</i> , 2018, 43, 251-257.	0.4	8
51	Natural history of ¹⁸ F-PSMA biochemically failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	1.3	12
52	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	2.6	6
53	Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1265-1275.	0.4	5
54	Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. , 2018, , 81-99.		0

#	ARTICLE	IF	CITATIONS
55	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	1.3	10
56	Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. <i>Cancer</i> , 2017, 123, 1635-1642.	2.0	14
57	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.	0.2	76
58	Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards. <i>Advances in Radiation Oncology</i> , 2017, 2, 503-514.	0.6	20
59	Independent surgical validation of the new prostate cancer grade-grouping system. <i>BJU International</i> , 2016, 118, 763-769.	1.3	48
60	MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. <i>Neoplasia</i> , 2016, 18, 213-222.	2.3	51
61	Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. <i>Eur Urol</i> 2016;69:50-7. <i>European Urology</i> , 2016, 70, e159.	0.9	0
62	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016, 1, 59-66.	0.6	6
63	Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 50-57.	0.9	30
64	Salvage Radiation Therapy Improves Metastasis-free Survival for Clinically Aggressive and Indolent Prostate Cancer Recurrences After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 367-372.	0.6	2
65	Time to Nadir PSA. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 465-471.	0.6	13
66	Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. <i>Radiation Oncology</i> , 2014, 9, 245.	1.2	2
67	A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. <i>Practical Radiation Oncology</i> , 2014, 4, 422-429.	1.1	7
68	Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 81-94.	1.1	34
69	Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, 99-107.	1.1	9
70	A prostate-specific antigen doubling time of ≤ 6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. <i>Radiation Oncology</i> , 2013, 8, 170.	1.2	22
71	Age and Comorbid Illness Are Associated With Late Rectal Toxicity Following Dose-Escalated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1246-1253.	0.4	43
72	Larger Maximum Tumor Diameter at Radical Prostatectomy Is Associated With Increased Biochemical Failure, Metastasis, and Death From Prostate Cancer After Salvage Radiation for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 275-281.	0.4	10

#	ARTICLE	IF	CITATIONS
73	The Interval to Biochemical Failure Is Prognostic for Metastasis, Prostate Cancer-Specific Mortality, and Overall Mortality After Salvage Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 554-561.	0.4	16
74	Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry. <i>Head and Neck</i> , 2013, 36, n/a-n/a.	0.9	50
75	Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. <i>Cancer</i> , 2013, 119, 3287-3294.	2.0	51